Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROArCT: Integrated Preoperative Radiotherapy and Chemotherapy in Rectal Cancer
NCT01013805Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Nov 2009
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Tolerability Rate at 11 weeks. Started Nov 2009; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01013805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013805.